Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jasgit Sachdev, MD
IDEAYA Biosciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Kinghorn Cancer Centre, St Vincent'S Health Network Sydney
Darlinghurst, New South Wales, Australia
- Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia
- Institut Bergonie
Bordeaux, Bordeaux Cedex, France
- Institut Claudius Regaud - Iuct-Oncopole
Toulouse, Cedex 9, France
- Hôpital Timone
Marseille, Marseille, France
- Centre Georges Francois Leclerc
Dijon, France
- Centre Eugène Marquis
Rennes, France
- Gustave Roussy
Villejuif, France
- Universitaetsklinikum Hamburg-Eppendorf (uke)
Hamburg, Germany
- National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
- Cha University - Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
- Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
- Asan Medical Center
Seoul, South Korea
- Samsung Medical Center
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Sevrance Hospital
Seoul, South Korea
- Hospital Universitario 12 de Octubre (h12o)
Madrid, Spain
- Next Madrid, Universitary Hospital Quironsalud
Madrid, Spain
- Start Madrid-Hm - Centro Integral Oncológico Clara Campal (ciocc)
Madrid, Spain
- Instituto Valenciano de Oncología (ivo)
Valencia, Spain
- National Cheng Kung University Hospital
Tainan, Tainan, Taiwan
- National Taiwan University Hospital
Taipei, Taipei, Taiwan
- Honor Health Research Institute
Scottsdale, Arizona, United States
- Rockefeller Cancer Institute
Little Rock, Arkansas, United States
- City of Hope
Duarte, California, United States
- Orlando Health Cancer Institute
Orlando, Florida, United States
- Indiana University Health Hospital
Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Columbia University Medical Center - Herbert Irving Pavilion
New York, New York, United States
- Weill Cornell Medical College
New York, New York, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Lifespan - Brown University
Providence, Rhode Island, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Md Anderson
Houston, Texas, United States
- Next Oncology
San Antonio, Texas, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Apr 2021
- Primary completion
- 7 Jan 2027
- Completion
- 4 Feb 2027
- Last update posted
- 9 Apr 2026
- Registered enrollment
- 169
- Registry id
- NCT04794699
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.